Activites

• 2015/09/30 Final act published in Official Journal
• 2015/04/29 Results of vote in Parliament
  • Results of vote in Parliament
  • T8-0167/2015 summary

    The European Parliament decided by 286 votes to 402, with 7 abstentions, to defer the decision to postpone granting discharge to Executive Director of the Innovative Medicines Initiative 2 (IMI) Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. With the rejection of the decision to postpone, discharge shall be granted and the accounts shall be deemed closed (see Annex V, Article 5(1) of the Rules of Procedure). Parliament also adopted by 633 votes to 42, with 17 abstentions, a resolution containing a number of recommendations that form an integral part of the discharge decision and as well as the general recommendations that appear in the resolution on performance, financial management and control of EU agencies: Budgetary and financial management: Parliament noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%.  Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Parliament asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. It also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. Members called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission. Internal control: Parliament observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings. Parliament went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2. Regarding the conflict of interests: Parliament took note that in order to prevent conflicts of interest in respect to its Governing Board members, experts and employees, the Joint Undertaking has put in place specific measures which are included in the rules of procedure of both the Governing Board and the Scientific Committee, as well as in the documentation on the code of conduct and conflicts of interest in the case of independent experts during evaluation. The Joint Undertaking has also adopted an updated and comprehensive policy on conflicts of interest for both management and staff members. Other observations: lastly, Parliament called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

• 2015/04/28 Debate in Parliament
  • Debate in Parliament
• 2015/03/31 Committee report tabled for plenary, single reading
  • A8-0106/2015 summary

    The Committee on Budgetary Control adopted the report by Ryszard CZARNECKI (ECR, PL) on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (IMI) for the financial year 2013. It called on the European Parliament to postpone its decision on granting the Executive Director of IMI 2 discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the IMI for the financial year 2013. Members postponed the closure of the accounts of the Joint Undertaking for the financial year 2013. At the same time, they made a number of recommendations that needed to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies. Budgetary and financial management: Members noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%.  Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Members asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. Members also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. They also called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission. Internal control: the committee observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings. Members went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2. Other observations: lastly, the committee called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

• 2015/03/23 Vote in committee, 1st reading/single reading
• 2014/10/20 Committee referral announced in Parliament, 1st reading/single reading
• 2014/07/30 Non-legislative basic document published
  • COM(2014)0510 summary

    PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure. Analysis of the accounts of the Joint Technology Initiative on Innovative Medicines (IMI). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the IMI Joint Undertaking. The document contains the figures on which the discharge procedure is based. Discharge procedure of the EU Joint Undertakings: the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies. The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective. The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies and Joint Undertakings (JUs) do not have a separate budget inside the EU budget; and they are partially financed by a Commission budget subsidy. Each JU is subject to its own discharge procedure. IMI: in 2013, the tasks and budget of the Joint Undertaking were as follows: description of the tasks of the Joint Undertaking: the IMI Joint undertaking, which is located in Brussels, was set up in 2007 by Council Regulation (EC) No 73/2008 for a period of 10 years. The IMI Joint Undertaking supports pre-competitive pharmaceutical research and development in the Member States and associated countries, aiming at increasing the research investment in the biopharmaceutical sector and promotes the involvement of small and medium-sized enterprises (SME) in its activities; accounts of the JU: the maximum indicative contribution of the Commission to cover running costs and research activities is EUR 1 billion up to 31.12.2017. The cumulative unrecognised share of losses is EUR 16 million. Please also consult the final accounts of IMI Joint Undertaking.

  • DG {'url': 'http://ec.europa.eu/dgs/budget/', 'title': 'Budget'}, GEORGIEVA Kristalina

Documents

• Non-legislative basic document published: COM(2014)0510
• Committee report tabled for plenary, single reading: A8-0106/2015
• Debate in Parliament: Debate in Parliament
• Results of vote in Parliament: Results of vote in Parliament
• Decision by Parliament, 1st reading/single reading: T8-0167/2015

Amendments

Dossier

13

2014/2133(DEC) 2015/03/05 CONT 13 amendments... Amendment 1 # Ingeborg GRÄSSLE, Marian-Jean MARINESCU Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013 / Postpones its decision on granting the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013; Amendment 10 # Marian-Jean MARINESCU Motion for a resolution Paragraph 8 a (new) 8 a. Notes the Joint Statement by the European Parliament, the Council and the Commission and the subsequent political agreement reached on the separate discharge to be given by the European Parliament upon recommendation of the Council, for Joint Undertakings under Article 209 of the Financial Regulation Amendment 11 # Marian-Jean MARINESCU Motion for a resolution Paragraph 8 b (new) 8 b. Calls on the Court to present a complete and appropriate financial assessment of rights and obligations of the Joint Undertaking for the period up to the date of Innovative Medicines Initiative 2 Joint Undertaking starting activity. Amendment 12 # Marian-Jean MARINESCU Motion for a resolution Paragraph 9 a (new) 9 a. Calls on the Joint Undertaking to submit a report to the discharge authority on the social-economic benefits of the already completed projects; calls for that report to be submitted to the discharge authority together with an assessment by the Commission; Amendment 13 # Marian-Jean MARINESCU Motion for a resolution Paragraph 16 a (new) 16 a. Recalls that the discharge authority has previously requested that the Court draws up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes Amendment 2 # Richard ASHWORTH, Richard SULÍK, Beata GOSIEWSKA Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013 / Postpones its decision on granting the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013; Amendment 3 # Ingeborg GRÄSSLE, Marian-Jean MARINESCU Proposal for a decision 2 Paragraph 1 1. Approves the closure of the accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013 / Postpones the closure of the accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013; Amendment 4 # Richard ASHWORTH, Richard SULÍK, Beata GOSIEWSKA Proposal for a decision 2 Paragraph 1 1. Approves the closure of the accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013 / Postpones the closure of the accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013; Amendment 5 # Marian-Jean MARINESCU Motion for a resolution Recital C C. whereas the maximum contribution for the period of 10 years from the Union to the Joint Undertaking is EUR 1 000 000 000, to be paid from the budget of the Seventh Research Framework Programme and the founding members are to contribute equally to the running costs, each with an amount not exceeding 4 % of the total Union contribution, and to the Research Activities with in-kind contributions at least equal to the financial contribution of the Community; Amendment 6 # Ingeborg GRÄSSLE Motion for a resolution Paragraph 4 a (new) 4 a. Calls on the Joint Undertaking for a follow-up report on the reservations of the Joint Undertaking in the last 3 years; Amendment 7 # Marian-Jean MARINESCU Motion for a resolution Paragraph 5 a (new) 5 a. Asks for an Action Plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner, to be followed by a first interim evaluation report on the implementation of the above-mentioned action plan Amendment 8 # Ingeborg GRÄSSLE Motion for a resolution Paragraph 6 a (new) 6 a. Calls on the Joint Undertaking to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in- kind contributions and their respective value; Amendment 9 # Marian-Jean MARINESCU Motion for a resolution Paragraph 7 a (new) 7 a. Calls on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission; source: 549.353

History

(these mark the time of scraping, not the official date of the change)